LC3I Cancer Research Results

LC3I, Lysosomal-associated membrane protein 2A: Click to Expand ⟱
Source:
Type:
LC3I (Lysosomal-associated membrane protein 2A, also known as LAMP2A) is a protein that plays a crucial role in the process of chaperone-mediated autophagy (CMA). CMA is a type of autophagy, a cellular process in which cells recycle and remove damaged or dysfunctional components.
LC3I is overexpressed in certain types of cancer, including breast, lung, and colon cancer.
The conversion of LC3-I to LC3-II (the lipidated form) is a key step in autophagy activation.

: In many cancers, low levels of LC3-I may indicate impaired autophagy, which can lead to the accumulation of damaged proteins and organelles, contributing to tumorigenesis. This is often associated with poor prognosis.
Tumor Promoting Role: In some contexts, the presence of LC3-I may indicate a baseline level of autophagy that is necessary for cellular homeostasis, but its role is less prominent compared to LC3-II.
Generally, decreased expression of LC3-I is associated with worse prognosis in many cancers, indicating its potential role in tumor suppression through the regulation of autophagy. However, the context-dependent nature of LC3-I's function suggests that further research is needed to fully understand its roles in different cancer types and its potential as a therapeutic target.


Scientific Papers found: Click to Expand⟱
5680- BML,    Anticancer properties of bromelain: State-of-the-art and recent trends
- Review, Var, NA
*Inflam↓, anticancer, anti-edema, anti-inflammatory, anti-microbial, anti-coagulant, anti-osteoarthritis, anti-trauma pain, anti-diarrhea, wound repair.
*Bacteria↓,
*Pain↓,
*Diar↓,
*Wound Healing↑,
ERK↓, Figure 1
JNK↓,
XIAP↓,
HSP27↓,
β-catenin/ZEB1↓,
HO-1↓,
lipid-P↓,
ACSL4↑,
ROS↑,
SOD↑,
Catalase↓,
GSH↓,
MDA↓,
Casp3↓,
Casp9↑,
DNAdam↑,
Apoptosis↑,
NF-kB↓,
P53↑,
MAPK↓,
APAF1↑,
Cyt‑c↓,
CD44↓,
Imm↑, Bromelain was also studied in the innate immune system, where it could enhance and sustain the process
ATG5↑,
LC3I↑,
Beclin-1↑,
IL2↓, bromelain in vitro experiments resulted in diminished amounts of IL-2, IL-6, IL-4, G-CSF, Gm-CSF, IFN-γ,
IL4↓,
IFN-γ↓,
COX2↓, proprietary bromelain extract could decrease IL-8, COX-2, iNOS, and TNF-α without affecting cell viability.
iNOS↓,
ChemoSen↑, Bromelain may increase the cytotoxicity of cisplatin in the treatment of breast cancer as reported in 2 studies with MDA-MB-231 and 4T1 Breast Tumor cell lines
RadioS↑, The size and weight of tumors in gamma-irradiated EST-bearing mice treated with bromelain decreased significantly with a significant amelioration in the histopathological examination
Dose↝, oral bromelain administration in breast cancer patients (daily up to a dose of 7800 mg)
other↓, The role of bromelain (in combination with papain, sodium selenite and Lens culinaris lectin) has been also tested as a complementary medicine on more than 600 breast cancer patients to reduce the side effects caused by the administration of the adju

1917- JG,    Inhibition of human leukemia cells growth by juglone is mediated via autophagy induction, endogenous ROS production, and inhibition of cell migration and invasion
- in-vitro, AML, HL-60
selectivity↑, revealed significant, selective (less cytotoxicity towards normal cells) and dose-dependent inhibition of HL-60 leukemia cells
LC3I↑, significant increase in LC3-I and LC3-II
LC3II↑,
Beclin-1↑, slight increase in Beclin-I
ROS↑, Confocal microscopy revealed tremendous increase in ROS concentrations in a dose-dependent manner
tumCV↓,
Dose↝, ROS percentage was 8%, with 20 μM dose it was 25% and with 80 μM its highest value was observed. dose-dependent increase in ROS production
TumAuto↑, The growth inhibitory effects of juglone were mediated via autophagy induction, endogenous ROS production, and inhibition of cell migration and invasion.

2232- SK,    Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis
- in-vitro, ESCC, EC9706
tumCV↓, Shikonin exposure repressed cell viability and migration and invasion capabilities and caused EC9706 cell autophagy and apoptosis by activating the AMPK/mTOR/ULK axis.
TumCMig↓,
TumCI↓,
TumAuto↑,
Apoptosis↑,
Bcl-2↓, Bcl-2 protein expressions were decreased; nevertheless, the protein expression of Bax, cleaved caspase3, cleaved caspase-8, and cleaved PARP were elevated with increasing concentrations of shikonin
BAX↑,
cl‑Casp3↑,
cl‑Casp8↑,
cl‑PARP↑,
AMPK↑, Shikonin-Induced Autophagy and Apoptosis Through Activation of AMPK/mTOR/ULK Pathway
mTOR↑,
TumVol↓, The tumor diameter is reduced by more than 25%, the response rate is 37%, and the 1-year survival rate is 47%
OS↑,
LC3I↑, Similarly, shikonin can upregulate the protein expression of LC3 in EC9706 cells


Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   GSH↓, 1,   HO-1↓, 1,   lipid-P↓, 1,   MDA↓, 1,   ROS↑, 2,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACSL4↑, 1,   AMPK↑, 1,  

Cell Death ⓘ

APAF1↑, 1,   Apoptosis↑, 2,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↓, 1,   cl‑Casp3↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 1,   Cyt‑c↓, 1,   iNOS↓, 1,   JNK↓, 1,   MAPK↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

HSP27↓, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 2,   LC3I↑, 3,   LC3II↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   P53↑, 1,   cl‑PARP↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 1,   ERK↓, 1,   mTOR↑, 1,  

Migration ⓘ

TumCI↓, 1,   TumCMig↓, 1,   β-catenin/ZEB1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IFN-γ↓, 1,   IL2↓, 1,   IL4↓, 1,   Imm↑, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose↝, 2,   RadioS↑, 1,   selectivity↑, 1,  

Functional Outcomes ⓘ

OS↑, 1,   TumVol↓, 1,  
Total Targets: 51

Pathway results for Effect on Normal Cells:


Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Functional Outcomes ⓘ

Pain↓, 1,   Wound Healing↑, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 1,   Diar↓, 1,  
Total Targets: 5

Scientific Paper Hit Count for: LC3I, Lysosomal-associated membrane protein 2A
1 Bromelain
1 Juglone
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:720  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page